PDRadiopharma will deliver a presentation at Interdisciplinary Symposium 9 of The 64th Annual Meeting of Japanese Society of Clinical Oncology (JSCO 2026) to be held from October 22 to 24, 2026.

PDRadiopharma announces that its President and Representative Director, Masato Murakami, will deliver a presentation titled “Implementation Challenges in Bringing Targeted Alpha Therapy to Patients.”
While targeted alpha therapy is expected to become a promising treatment option in cancer care, various challenges remain in its practical implementation, including not only research and development but also manufacturing and supply systems as well as readiness in clinical practice.

In this presentation, Masato Murakami will discuss the challenges involved in delivering targeted alpha therapy to patients in a stable and sustainable manner, as well as initiatives aimed at addressing these challenges.

PDRadiopharma remains committed to creating new value for patients through the research, development, manufacturing, and stable supply of radiopharmaceuticals.